Abstract
Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1,186 subjects, from the GEN-COVID consortium, infected by SARS-CoV-2 with different severity were stratified by sex and adjusted by age. Then, common coding variants from whole exome sequencing were mined by LASSO logistic regression. The homozygosity of the cell adhesion molecule P-selectin gene (SELP) rs6127 (c.1807G>A; p.Asp603Asn) which increases platelet activation is found to be associated with severity in the male subcohort of 513 subjects (Odds Ratio= 2.27, 95% Confidence Interval 1.54-3.36). As the SELP gene is downregulated by testosterone, the odd ratio is increased in males older than 50 (OR 2.42, 95% CI 1.53-3.82). Asn/Asn homozygotes have increased D-dimers values especially when associated with poly Q≥23 in the androgen receptor (AR) gene (OR 3.26, 95% CI 1.41-7.52). These results provide a rationale for the repurposing of antibodies against P-selectin as adjuvant therapy in rs6127 male homozygotes especially if older than 50 or with impaired AR gene.
Key points
○ The functional polymorphism rs6127 (p.Asp603Asn) in the testosterone-regulated SELP gene associates with COVID-19 severity and thrombosis.
○ Conditions with decreased testosterone (old males), or decreased testosterone efficacy (AR gene polyQ ≥ 23) strengthen the association.
INTRODUCTION
Since its onset in early 2020, the global pandemic of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has posed a multitude of challenges and triggered intensive research on the disease and the virus. However, a lot of questions still remain unanswered, especially those regarding its heterogeneity of clinical manifestations and the appropriate therapeutic strategies.
It is now widely recognized that COVID-19 is a systemic disease1 characterized by dysregulation of the immune system and presence of a hypercoagulable state2. COVID-19 severe patients show coagulation abnormalities with increased incidence of arterial thrombosis and mortality has been shown to correlate with elevated levels of both interleukin-6 (IL-6) and D-dimer2,3. These values have often been reported accompanied by a relatively modest decrease in platelet count4, and prolongation of the prothrombin time3.
Genetic bases of this prothrombotic susceptibility remain until now elusive, despite the fact that it is evident that phenotypic variability associated with the viral infection is obviously also due to host genetic factors. Some rare variants of genes involved in adaptive immunity have been identified by us and others in Mendelian forms of COVID-195-7. Among common genetic factors, the protective role of the zero blood group has been linked to destabilization of the von Willebrand factor and protection from thrombosis8. We have shown that longer polyQ repeats (≥ 23) in the androgen receptor gene (AR) predisposes to severe COVID-19 outcome due to reduced anti-inflammatory and anti-thrombotic effect of testosterone9.
The testosterone inhibited P-selectin (SELP) gene encodes a cell adhesion molecule that is stored in the alpha-granules of platelets and in Weibel-Palade bodies of endothelial cells. It mediates the interaction of activated platelets on endothelium with leukocytes playing a key role in the thrombotic process10,11. A significantly increased P-selectin concentration in plasma samples of severe COVID-19 patients compared to healthy controls, together with other prothrombotic biomarkers has been recently demonstrated12,13.
Among SELP variants, the Asp603Asn functional polymorphism (rs6127; c.1807G>A) - previously reported as Asp562Asn or Asp541Asn - has been associated with risk of thrombotic disease, tissue damage in diabetes, abortion, as well as myocardial infarction14-18. The polymorphism is located within the consensus repeat domain of the SELP protein19, and it has been shown to affect the binding of P-selectin to its ligand (PSGL-1) on leukocytes, resulting in a protein that is more efficient at recruiting leukocytes to the endothelium16.
Here, we applied Ordered Logistic Regression (OLR) analysis on clinical data and LASSO logistic regression on WES data within our prospectively recruited GEN-COVID cohort and identified SELP as a key player for severity and thromboembolism in severe COVID-19.
MATERIAL AND METHODS
A cohort of 1,186 SARS-CoV-2-infected subjects was recruited during the first pandemic wave within the Italian GEN-COVID Study (https://sites.google.com/dbm.unisi.it/gen-covid)1. ORL model was applied to the clinical WHO gradings, stratified by sex and adjusted by age, as described elsewhere20. The male subset consists of 513 COVID-19 male patients: 236 severe COVID-19 patients (cases) and 277 SARS-CoV-2 PCR-positive oligo-asymptomatic subjects (controls). WES with at least 97% coverage at 20x was performed using the NovaSeq6000 System (Illumina, San Diego, CA, USA) as previously described1. WES data were represented in a binary mode on a gene-by-gene basis20. LASSO logistic regression model was applied to a synthetic boolean representation under recessive model of genetic combinations 20. Association was confirmed by Chi Square Test. Longitudinal laboratory values were represented by linear graphs. Differences were assessed by Mann–Whitney test and displayed by box plots. Statistical procedures were carried out using R packages.
RESULTS AND DISCUSSION
Within the Italian GEN-COVID cohort, we tested different combination of coding polymorphisms of human genes at homozygous state and found that the Asp603Asn polymorphism of the SELP gene correlate with severity in the subcohort of males (Figure 1, panel A) 1,20. The genotypic frequencies of the polymorphism in cases and controls were confirmed to be in Hardy-Weinberg equilibrium; the minor allele frequency in our cohort was similar to that reported in the European (non-Finnish) population in the gnomAD database (16.4% versus 15.9%) (https://gnomad.broadinstitute.org/).
We reasoned that the hyper-inflammatory and hyper-thrombotic state, due to viral injury of the vascular endothelium, leads to the release of P-selectin by activated platelets, driving thrombosis and vascular inflammation especially in those individuals with enhanced P-selectin activities due a double copy of Asparagine in position 603 without any other additional coding polymorphisms16. These results are in line with the demonstration that SARS-CoV-2 induces thrombosis by binding to ACE2 on platelets and subsequent integrin αIIbβ3 activation and P-selectin expression21, and that P-selectin soluble isoform is increased in thrombosis10,11 and severe COVID-1912,13.
The association between Asp603Asn polymorphism (rs6127) in homozygous state, in absence of other coding polymorphisms, and severity is quite strong with an OR 2.27 in males (95% CI, 1.54 to 3.36; p-value 2.8×10−5, Table 1a). We reasoned that, since SELP transcription is inhibited by androgens22, the strength of the association should increase with age. Indeed, in males aged ≥ 50 years we found an increased OR of 2.42 (95% CI, 1.53 to 3.82; p-value 1.19×10−4, Table 1b). While the significance is, instead, lost in young males (<50 years), (data not shown p= 1.1×10−1).
In a subset of 52 severely affected hospitalised males, 4 main laboratory parameters indicating thrombosis (D-dimer, platelets and LDH) and severity (lymphocytes) were longitudinally followed (Figure 1, Panel B-E). We observed that the maximum pick, over 10 times of the normal value, was exclusive of Asp/Asn and Asn/Asn genotypes and older patients (Figure 1, Panel B-E). The pick timing was earlier in Asn/Asn (median 7.5 days from infection) than Asp/Asn (median 13.5 days from infection), (p-value = 3×10−2, Figure 1, panel F). As the von Willebrand factor (vWF) is a downstream effector for clotting, the non-zero blood group, associating with more stable vWF, also correlate with higher D-dimer and LDH values (Figure 1, panel G-H), in agreement with previous reports8.
Given the higher association of the SELP polymorphism in older males we reasoned that the AR poly-Q status would impact on the SELP genotype9: the combination of poly-Q polymorphism ≥ 23 with homozygous SELP polymorphism versus D-dimer value reached an OR of 3.26 (95% CI 1.41-7.52; p-value 3.73×10−3), (Table 1c). This result indicates that the two polymorphisms enhance each other, and that the SELP Asp603Asn and the AR poly-Q are two factors belonging to the same puzzle contributing to thrombosis in COVID-19 in males.
Anti-P-Selectin monoclonal antibodies have been developed for human use: the phase 3 Inclacumab and the FDA and EMA approved Crizanlizumab. The latter is indicated to prevent vaso-occlusive crises in patients with sickle cell disease and to decrease inflammation, blocking leucocyte and platelet adherence to the vessel wall23-25. A general clinical trial to test the efficacy and safety of Crizanlizumab in patients hospitalized with COVID-19 is ongoing (https://clinicaltrials.gov/ct2/show/study/NCT04435184), in not selected patients. Clinical trials in COVID-19 hospitalised males with SELP rs6127 c.1807G>A p.Asp603Asn should be encouraged.
In conclusion, we identified SELP rs6127 polymorphism as the elusive genetic factor predisposing COVID-19 patients to thromboembolism leading to life-threatening disease. We showed that predisposition increases if the protective effect of testosterone is lost either by age or because of additional genetic factors such as poly Q≥23 in the AR gene. This knowledge provides a rationale for repurposing anti P-selectin monoclonal antibodies as personalized adjuvant therapy in men affected by COVID-19.
Data Availability
The data and samples referenced here are housed in the GEN-COVID Patient Registry and the GEN-COVID Biobank and are available for consultation. You may contact the corresponding author, Prof. Alessandra Renieri (e-mail: alessandra.renieri{at}unisi.it).
AUTHORSHIP
Contribution
AR, FM and EF designed the study; CF, SD, EB, NP, KZ, FC, VB, GB, LDS, DA, SL, SC, MP, AB, GM, AMI, EF, SF analysed the data; EB, KZ, NP, SF performed statistical analysis; MB, FF and GEN-COVID Multicenter Study provided clinical data; AR and FM supervised the study and all authors edited the manuscript and approved its final version.
Conflict-of-interest disclosure
All the authors declare no competing financial interests.
ETHICS APPROVAL
The study (GEN-COVID) was consistent with Institutional guidelines and approved by the University Hospital (Azienda Ospedaliero-Universitaria Senese) Ethical Review Board, Siena, Italy (Prot n. 16929, dated March 16, 2020).
DATA AVAILABILITY STATEMENT
The data and samples referenced here are housed in the GEN-COVID Patient Registry and the GEN-COVID Biobank and are available for consultation. You may contact the corresponding author, Prof. Alessandra Renieri (e-mail: alessandra.renieri{at}unisi.it).
CONFLICT OF INTEREST
All the authors declare no competing financial interests.
GEN-COVID Multicenter Study (https://sites.google.com/dbm.unisi.it/gen-covid)
Floriana Valentino1,2, Gabriella Doddato1,2, Annarita Giliberti1,2, Rossella Tita7, Sara Amitrano7, Mirella Bruttini1,2,7, Ilaria Meloni1,2, Anna Maria Pinto7, Maria Antonietta Mencarelli7, Caterina Lo Rizzo7, Francesca Montagnani2,8, Miriam Lucia Carriero1,2, Massimiliano Fabbiani8, Ilaria Rancan8, Barbara Rossetti8, Mario Tumbarello2,8, Elena Bargagli9, Laura Bergantini9, Miriana D’Alessandro9, Paolo Cameli9, David Bennett9, Federico Anedda10, Simona Marcantonio10, Sabino Scolletta10, Federico Franchi10, Maria Antonietta Mazzei11, Susanna Guerrini11, Edoardo Conticini12, Luca Cantarini12, Bruno Frediani12, Danilo Tacconi13, Chiara Spertilli Raffaelli13, Marco Feri14, Alice Donati14, Raffaele Scala15, Luca Guidelli15, Genni Spargi16, Marta Corridi16, Cesira Nencioni17, Leonardo Croci17, Gian Piero Caldarelli18, Maurizio Spagnesi19, Paolo Piacentini19, Maria Bandini19, Elena Desanctis19, Silvia Cappelli19, Anna Canaccini20, Agnese Verzuri20 Valentina Anemoli20, Agostino Ognibene21, Alessandro Pancrazi21, Maria Lorubbio21, Massimo Vaghi22, Antonella D’Arminio Monforte23, Esther Merlini23, Federica Gaia Miraglia23, Mario U. Mondelli24,25, Raffaele Bruno24,25, Marco Vecchia24,, Stefania Mantovani24, Serena Ludovisi24,25, Massimo Girardis26, Sophie Venturelli26, Stefano Busani26, Andrea Cossarizza27, Andrea Antinori28 Alessandra Vergori28, Arianna Emiliozzi28, Stefano Rusconi29,30, Matteo Siano30, Arianna Gabrieli30, Agostino Riva29,30, Daniela Francisci31,32, Elisabetta Schiaroli31, Francesco Paciosi31, Andrea Tommasi31, Pier Giorgio Scotton33, Francesca Andretta33, Sandro Panese34, Renzo Scaggiante35, Francesca Gatti35, Saverio Giuseppe Parisi36, Francesco Castelli37, Eugenia Quiros-Roldan37, Melania degli Antoni37, Isabella Zanella38, Matteo Della Monica39, Carmelo Piscopo39, Mario Capasso40,41,42, Roberta Russo40,42, Immacolata Andolfo40,41, Achille Iolascon40,41, Giuseppe Fiorentino43, Massimo Carella44, Marco Castori44, Filippo Aucella45, Pamela Raggi46, Carmen Marciano46, Rita Perna46, Matteo Bassetti47,48, Antonio Di Biagio48 Maurizio Sanguinetti49,50, Luca Masucci49,50, Serafina Valente51, Oreste De Vivo51, Marco Mandalà52, Alessia Giorli52, Lorenzo Salerni52, Patrizia Zucchi53, Pierpaolo Parravicini53, Elisabetta Menatti54, Stefano Baratti55, Tullio Trotta56, Ferdinando Giannattasio56, Gabriella Coiro56, Fabio Lena57, Domenico A. Coviello58, Cristina Mussini59, Giancarlo Bosio60, Enrico Martinelli60, Sandro Mancarella61, Luisa Tavecchia61, Mary Ann Belli61, Lia Crotti62,63,64,65,66, Gianfranco Parati62,63, Marco Gori4,67, Chiara Gabbi68, Maurizio Sanarico69, Stefano Ceri70, Pietro Pinoli70, Francesco Raimondi71, Filippo Biscarini72, Alessandra Stella72, Marco Rizzi73, Franco Maggiolo73, Diego Ripamonti73, Claudia Suardi74, Tiziana Bachetti75, Maria Teresa La Rovere76, Simona Sarzi-Braga77, Maurizio Bussotti78 Simona Dei79, Katia Capitani2,80, Sabrina Ravaglia81, Rosangela Artuso82, Antonio Perrella83, Francesco Bianchi2,83, Davide Romani19, Paola Bergomi84, Emanuele Catena84, Riccardo Colombo84, Sauro Luchi85, Giovanna Morelli85, Paola Petrocelli85, Valentina Perticaroli1,2,7, Mirjam Lista1,2, Silvia Baroni86, Francesco Vladimiro Segala87, Alessandra Guarnaccia49, Giuseppe Merla40,88, Gabriella Maria Squeo88
8. Dept of Specialized and Internal Medicine, Tropical and Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
9. Unit of Respiratory Diseases and Lung Transplantation, Department of Internal and Specialist Medicine, University of Siena
10 Dept of Emergency and Urgency, Medicine, Surgery and Neurosciences, Unit of Intensive Care Medicine, Siena University Hospital, Italy
11. Department of Medical, Surgical and Neurosciences and Radiological Sciences, Unit of Diagnostic Imaging, University of Siena
12 Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Italy
13. Department of Specialized and Internal Medicine, Infectious Diseases Unit, San Donato Hospital Arezzo, Italy
14. Dept of Emergency, Anesthesia Unit, San Donato Hospital, Arezzo, Italy
15. Department of Specialized and Internal Medicine, Pneumology Unit and UTIP, San Donato Hospital, Arezzo, Italy
16. Department of Emergency, Anesthesia Unit, Misericordia Hospital, Grosseto, Italy
17. Department of Specialized and Internal Medicine, Infectious Diseases Unit, Misericordia Hospital, Grosseto, Italy
18. Laboratory Medicine Department, Misericordia Hospital, Grosseto, Italy
19. Department of Preventive Medicine, Azienda USL Toscana Sud Est, Italy
20. Territorial Scientific Technician Department, Azienda USL Toscana Sud Est, Italy
21. Laboratory Medicine Department, San Donato Hospital, Arezzo, Italy
22. Chirurgia Vascolare, Ospedale Maggiore di Crema, Italy
23. Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy
24. Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
25. Department of Internal Medicine and Therapeutics, University of Pavia, Italy
26. Department of Anesthesia and Intensive Care, University of Modena and Reggio Emilia, Modena, Italy
27. Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
28. HIV/AIDS Department, National Institute for Infectious Diseases, IRCCS, Lazzaro Spallanzani, Rome, Italy
29. III Infectious Diseases Unit, ASST-FBF-Sacco, Milan, Italy
30. Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy
31. Infectious Diseases Clinic, Department of Medicine, Azienda Ospedaliera di Perugia and University of Perugia, Santa Maria Hospital, Perugia, Italy
32. Infectious Diseases Clinic, “Santa Maria” Hospital, University of Perugia, Perugia, Italy
33. Department of Infectious Diseases, Treviso Hospital, Local Health Unit 2 Marca Trevigiana, Treviso, Italy
34. Clinical Infectious Diseases, Mestre Hospital, Venezia, Italy.
35. Infectious Diseases Clinic, ULSS1, Belluno, Italy
36. Department of Molecular Medicine, University of Padova, Italy
37. Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
38. Department of Molecular and Translational Medicine, University of Brescia, Italy; Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Italy
39. Medical Genetics and Laboratory of Medical Genetics Unit, A.O.R.N. “Antonio Cardarelli”, Naples, Italy
40. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
41. CEINGE Biotecnologie Avanzate, Naples, Italy
42. IRCCS SDN, Naples, Italy
43. Unit of Respiratory Physiopathology, AORN dei Colli, Monaldi Hospital, Naples, Italy
44. Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
45. Department of Medical Sciences, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
46. Clinical Trial Office, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
47. Department of Health Sciences, University of Genova, Genova, Italy
48. Infectious Diseases Clinic, Policlinico San Martino Hospital, IRCCS for Cancer Research Genova, Italy
49. Microbiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Medicine, Rome, Italy
50. Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
51. Department of Cardiovascular Diseases, University of Siena, Siena, Italy
52. Otolaryngology Unit, University of Siena, Italy
53. Department of Internal Medicine, ASST Valtellina e Alto Lario, Sondrio, Italy
54. Study Coordinator Oncologia Medica e Ufficio Flussi, Sondrio, Italy
55. Department of Infectious and Tropical Diseases, University of Padova, Padova, Italy
56. First Aid Department, Luigi Curto Hospital, Polla, Salerno, Italy
57. Local Health Unit-Pharmaceutical Department of Grosseto, Toscana Sud Est Local Health Unit, Grosseto, Italy
58. U.O.C. Laboratorio di Genetica Umana, IRCCS Istituto G. Gaslini, Genova, Italy.
59. Infectious Diseases Clinics, University of Modena and Reggio Emilia, Modena, Italy.
60. Department of Respiratory Diseases, Azienda Ospedaliera di Cremona, Cremona, Italy
61. U.O.C. Medicina, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo (MI), Italy
62. Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy.
63. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
64. Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy.
65. Istituto Auxologico Italiano, IRCCS, Laboratory of Cardiovascular Genetics, Milan, Italy.
66. Member of the European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart-ERN GUARD-Heart
67. University Cote d’Azur, Inria, CNRS, I3S, Maasai
68. Independent Medical Scientist, Milan, Italy
69. Independent Data Scientist, Milan, Italy
70. Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milano, Italy
71. Scuola Normale Superiore, Pisa, Italy
72. CNR-Consiglio Nazionale delle Ricerche, Istituto di Biologia e Biotecnologia Agraria (IBBA), Milano, Italy.
73. Unit of Infectious Diseases, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
74. Fondazione per la ricerca Ospedale di Bergamo, Bergamo, Italy
75. Direzione Scientifica, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
76. Istituti Clinici Scientifici Maugeri IRCCS, Department of Cardiology, Institute of Montescano, Pavia, Italy.
77. Istituti Clinici Scientifici Maugeri, IRCCS, Department of Cardiac Rehabilitation, Institute of Tradate (VA), Italy.
78. Cardiac Rehabilitation Unit, Fondazione Salvatore Maugeri, IRCCS, Scientific Institute of Milan, Milan, Italy.
79. Health Management, Azienda USL Toscana Sudest, Tuscany, Italy.
80. Core Research Laboratory, ISPRO, Florence, Italy
81. IRCCS C. Mondino Foundation, Pavia, Italy
82. Medical Genetics Unit, Meyer Children’s University Hospital, Florence, Italy
83. Department of Medicine, Pneumology Unit, Misericordia Hospital, Grosseto, Italy.
84. Department of Anesthesia and Intensive Care Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Polo Universitario, University of Milan, Milan
85. Infectious Disease Unit, Hospital of Lucca, Italy.
86. Department of Diagnostic and Laboratory Medicine, Institute of Biochemistry and Clinical Biochemistry, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
87. Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy.
88. Laboratory of Regulatory and Functional Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy
ACKNOWLEDGMENT
This study is part of the GEN-COVID Multicenter Study, https://sites.google.com/dbm.unisi.it/gen-covid, the Italian multicenter study aimed at identifying the COVID-19 host genetic bases. Specimens were provided by the COVID-19 Biobank of Siena, which is part of the Genetic Biobank of Siena, member of BBMRI-IT, of Telethon Network of Genetic Biobanks (project no. GTB18001), of EuroBioBank, and of RDConnect. We thank the CINECA consortium for providing computational resources and the Network for Italian Genomes (NIG) http://www.nig.cineca.it for its support. We thank private donors for the support provided to A.R. (Department of Medical Biotechnologies, University of Siena) for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). We also thank the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/), MIUR project “Dipartimenti di Eccellenza 2018-2020” to the Department of Medical Biotechnologies University of Siena, Italy and “Bando Ricerca COVID-19 Toscana’’ project to Azienda Ospedaliero Universitaria Senese. We also thank Intesa SanPaolo for the 2020 charity fund dedicated to the project “N. B/2020/0119 Identificazione delle basi genetiche determinanti la variabilità clinica della risposta a COVID-19 nella popolazione italiana’’; the Italian Ministry of University and Research for funding within the “Bando FISR 2020” in COVID-19 and and the Istituto Buddista Italiano Soka Gakkai for funding the project “PAT-COVID: Host genetics and pathogenetic mechanisms of COVID-19” (ID n. 2020-2016_RIC_3).